Nu Sri Shyam Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.25 Cr
as on 23-10-2024
- Paid Up Capital ₹ 1.18 Cr
as on 23-10-2024
- Company Age 11 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.54 Cr
as on 23-10-2024
- Satisfied Charges ₹ 3.50 Cr
as on 23-10-2024
- Revenue -15.84%
(FY 2023)
- Profit -16.59%
(FY 2023)
- Ebitda -6.22%
(FY 2023)
- Net Worth 21.17%
(FY 2023)
- Total Assets 4.23%
(FY 2023)
About Nu Sri Shyam Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.25 Cr and a paid-up capital of Rs 1.18 Cr.
The company currently has active open charges totaling ₹10.54 Cr. The company has closed loans amounting to ₹3.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Urmila Chokhani and Nishant Chokhani serve as directors at the Company.
- CIN/LLPIN
U51909WB2013PTC193074
- Company No.
193074
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 May 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Nu Sri Shyam Pharmaceuticals Private Limited offer?
Nu Sri Shyam Pharmaceuticals Private Limited offers a wide range of products and services, including Immunosuppressive Drugs, Tacrolimus Capsule, Common Disease Medicines, Hair Growth Medicine, Anti Infective Drugs & Medicines, Antibiotic Injection, Meropenem Injection, Amoxicillin drugs, Amoxicillin Potassium Clavulanate Tablet, Anti Cancer Medicines.
Who are the key members and board of directors at Nu Sri Shyam Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Urmila Chokhani  | Director | 09-May-2013 | Current |
| Nishant Chokhani | Director | 09-May-2013 | Current |
Financial of Nu Sri Shyam Pharmaceuticals.
Nu Sri Shyam Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 15.84% decrease. The company also saw a substantial fall in profitability, with a 16.59% decrease in profit. The company's net worth Soared by an impressive increase of 21.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nu Sri Shyam Pharmaceuticals?
In 2023, Nu Sri Shyam Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 05 Mar 2024 | ₹5.10 M | Open |
Others Creation Date: 18 Jun 2021 | ₹4.24 M | Open |
Others Creation Date: 03 Mar 2020 | ₹8.50 Cr | Open |
How Many Employees Work at Nu Sri Shyam Pharmaceuticals?
Nu Sri Shyam Pharmaceuticals has a workforce of 63 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nu Sri Shyam Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nu Sri Shyam Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
